BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15254059)

  • 21. Docetaxel vs. vinorelbine in elderly patients with advanced non--small-cell lung cancer: a hellenic oncology research group randomized phase III study.
    Karampeazis A; Vamvakas L; Agelidou A; Kentepozidis N; Chainis K; Chandrinos V; Vardakis N; Pallis AG; Christophyllakis C; Georgoulias V
    Clin Lung Cancer; 2011 May; 12(3):155-60. PubMed ID: 21663857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984).
    Biesma B; Manegold C; Smit HJ; Willems L; Legrand C; Passioukov A; van Meerbeeck JP; Giaccone G;
    Eur J Cancer; 2006 Jul; 42(10):1399-406. PubMed ID: 16759850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
    Gebbia V; Lorusso V; Galetta D; Caruso M M; Palomba G; Riccardi F; Borsellino N; Carrozza F; Leo S; Ferraù F; Cinieri S; Mancuso G; Mancarella S; Colucci G
    Lung Cancer; 2010 Aug; 69(2):218-24. PubMed ID: 19910076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequential administration of docetaxel followed by cisplatin-vindesine: a pilot study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
    Rixe O; Gatineau M; Jauffret E; Spano JP; Orcel B; Vannetzel JM; Berille J; Derenne JP; Khayat D
    Bull Cancer; 2005 Jan; 92(1):E1-6. PubMed ID: 15689321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-dose weekly docetaxel is as tolerable as pemetrexed in previously treated advanced non-small-cell lung cancer.
    Chung FT; Lee KY; Fang YF; Shieh MH; Lin SM; Yu CT; Lo YL; Lin TY; Kuo CH; Feng PH; Ni YL; Kuo HP
    Chemotherapy; 2011; 57(2):147-55. PubMed ID: 21454972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
    Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer.
    Kaira K; Tsuchiya S; Sunaga N; Yanagitani N; Watanabe S; Imai H; Hisada T; Ishizuka T; Saito R; Mori M
    Am J Clin Oncol; 2007 Feb; 30(1):51-6. PubMed ID: 17278895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.
    Hanna N; Neubauer M; Yiannoutsos C; McGarry R; Arseneau J; Ansari R; Reynolds C; Govindan R; Melnyk A; Fisher W; Richards D; Bruetman D; Anderson T; Chowhan N; Nattam S; Mantravadi P; Johnson C; Breen T; White A; Einhorn L; ;
    J Clin Oncol; 2008 Dec; 26(35):5755-60. PubMed ID: 19001323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer.
    Lai CL; Tsai CM; Chiu CH; Wang GS; Su WJ; Chen YM; Perng RP
    Jpn J Clin Oncol; 2005 Dec; 35(12):700-6. PubMed ID: 16303792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Open-label, randomized, single-dose, crossover study to evaluate the pharmacokinetics and safety differences between two docetaxel products, CKD-810 and Taxotere injection, in patients with advanced solid cancer.
    Cho EK; Park JY; Lee KH; Song HS; Min YJ; Kim YH; Kang JH
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):9-16. PubMed ID: 24337589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase 1 study of ombrabulin in combination with docetaxel and cisplatin in Japanese patients with advanced solid tumors.
    Nishio M; Satouchi M; Horiike A; Horio Y; Sunaga Y; Ecstein-Fraisse E; Hida T
    Jpn J Clin Oncol; 2018 Apr; 48(4):322-328. PubMed ID: 29514256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of advanced age and serum α
    Kenmotsu H; Imamura CK; Ono A; Omori S; Nakashima K; Wakuda K; Taira T; Naito T; Murakami H; Takahashi T; Tanigawara Y
    Br J Clin Pharmacol; 2017 Nov; 83(11):2416-2425. PubMed ID: 28640540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship of systemic exposure to unbound docetaxel and neutropenia.
    Baker SD; Li J; ten Tije AJ; Figg WD; Graveland W; Verweij J; Sparreboom A
    Clin Pharmacol Ther; 2005 Jan; 77(1):43-53. PubMed ID: 15637530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circadian variability of pharmacokinetics of cisplatin in patients with non-small-cell lung carcinoma: analysis with the NONMEM program.
    Chen R; Li J; Hu WW; Wang ML; Zou SL; Miao LY
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1111-23. PubMed ID: 24061864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia.
    Hansson EK; Friberg LE
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):881-90. PubMed ID: 22057837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics.
    Meille C; Iliadis A; Barbolosi D; Frances N; Freyer G
    J Pharmacokinet Pharmacodyn; 2008 Dec; 35(6):619-33. PubMed ID: 19107581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel.
    Cox MC; Low J; Lee J; Walshe J; Denduluri N; Berman A; Permenter MG; Petros WP; Price DK; Figg WD; Sparreboom A; Swain SM
    Clin Cancer Res; 2006 Aug; 12(15):4636-40. PubMed ID: 16899612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer.
    Zamboni WC; Combest AJ; DeLoia JA; Edwards RP; Bridges AS; Zamboni BA; Walko CM; Yu AY; Krivak TC; Kelley JL
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1255-62. PubMed ID: 21437702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical trial simulations for dosage optimization of docetaxel in patients with liver dysfunction, based on a log-binominal regression for febrile neutropenia.
    Ozawa K; Minami H; Sato H
    Yakugaku Zasshi; 2009 Jun; 129(6):749-57. PubMed ID: 19483418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neutropenic enterocolitis (typhilitis) associated with docetaxel therapy in a patient with non-small-cell lung cancer: case report and review of literature.
    D'Amato G; Rocha Lima C; Mahany JJ; Muro-Cacho C; Haura EB
    Lung Cancer; 2004 Jun; 44(3):381-90. PubMed ID: 15140552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.